Please login to the form below

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a fast-track review by the US FDA. ... AZ and Lilly are already carrying out one phase II/III placebo-controlled trial of AZD3293
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Sudler London - Senior Medical Writer: Competitive

Medical Writer - Creative and Scientific Projects: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager: Negotiable

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Systematic Review Lead- London: Negotiable

Associate Scientific Director: Salary TBC

Account Director or Senior Account Director: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Market Access Consultant - Greater Manchester: Negotiable

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Writer, Healthcare Advertising, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....